Solid Tumor Genetic Tests Detect&Act
An estimated 19.3 million new cancer cases and almost 10 million cancer deaths occurred worldwide in 2020. Solid tumors represent approximatively 90% of adult cancers and can develop in many parts of the body. In up to 40% of patients, complex genomic alterations were identified which can serve as biomarkers to predict response to a specific therapy and/or prognosis. Of roughly 25,000 genes in the human genome, 500 genes are likely linked to cancer, including those that are considered “driver genes” of cancer.
Genetic testing can determine the tumor profile and suggest appropriate management or treatment plans, if available. We offer molecular genetic analyses for solid tumors ranging from targeted-therapy tests to comprehensive panels.
Characterizing the genetic changes in a solid tumor is critical for possible targeted therapies. Customized treatment depends on the specific genetic alterations in the tumor tissue. Genotype directed therapy or genotype-matched clinical trials can improve patient care and survival.
IMPORTANCE OF GETTING TESTED
Tumor profiling allows for individualized and more efficient and personalized treatment, depending on the unique genetic alterations in the tumor, known as precision medicine. Treating a tumor based on its molecular features may result in better patient outcome, including improved clinical management and increased survival.
Patients diagnosed with a solid tumor
and have performed a pathology analysis
POSSIBLE OUTCOMES OF THE TEST
A molecular genetic diagnostic report outlining the results of the sequencing analysis is provided. Changes in DNA sequences (variants) can be detrimental and lead to the development of a cardiac or aortic disorder, including asymptomatic disorders that develop later in life. We will report pathogenic and likely pathogenic variants as well as variants of unknown significance.
Pathogenic and likely pathogenic variants mean the genetic cause of the observed symptoms has been identified and may help determine the right treatment and management plan.
Variants of unknown significance means there was not enough evidence to classify the variant as either pathogenic or neutral. Annual variant reclassification and testing family members is recommended.
It is important to note that a negative result does not guarantee the absence of a disorder or that the disorder does not have a genetic cause. Genetic testing is an evolving field and may not detect all variants or there may not currently be enough evidence to classify all variants that lead to an inherited disease.